MedTrace Logo

Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia

NCT01327014 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2014-07-23

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the efficacy of XueZhiKang to improve plasma lipid profile, as compared to placebo, in outpatients with hyperlipidemia.

Conditions

Interventions

DRUG

XueZhiKang (XZK), a botanic product with multiple components

4 capsules of study drug twice a day for 12 weeks.

DRUG

Placebo

4 capsules twice a day for 12 weeks.

Sponsors & Collaborators

  • Beijing Peking University WBL Biotech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • David Capuzzi · Cardiovascular Medical Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01327014 on ClinicalTrials.gov